Neuropace
NPCE
98 hedge funds and large institutions have $251M invested in Neuropace in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 23 reducing their positions, and 13 closing their positions.
4,264% more call options, than puts
Call options by funds: $35M | Put options by funds: $802K
100% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 23
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
9% more funds holding
Funds holding: 90 → 98 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.89% less ownership
Funds ownership: 73.5% → 68.62% (-4.9%)
15% less capital invested
Capital invested by funds: $294M → $251M (-$43.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.7M |
| 3 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$2.55M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.52M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$37.2M |
| 2 |
O
OrbiMed
New York
|
-$9.9M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.69M |
| 4 |
Millennium Management
New York
|
-$3.3M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$2.55M |
NPCE Hedge Fund Activity: Q2 2025 in Review
98 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q2 2025, worth a combined $251M — down 15% from $294M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NPCE positions and 13 closed out — a net gain of 8 holders — while 46 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $18.3M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $37.2M sold.
- 98 institutional investors held Neuropace (NPCE) as of Q2 2025, up from 90 in Q1 2025.
- Funds reported $251M of Neuropace stock for Q2 2025, down 15% quarter-over-quarter.
- 21 funds opened new Neuropace positions in Q2 2025 and 13 closed out, a net change of +8 holders.
- The largest Neuropace buyer in Q2 2025 was BlackRock, an estimated $18.3M added.
- The largest Neuropace seller in Q2 2025 was Polar Capital Holdings, an estimated $37.2M sold.
Based on aggregated 13F filings for Q2 2025.